Children's brain tumors more diverse than previously believed

May 14, 2012

Paediatric brain tumours preserve specific characteristics of the normal cells from which they originate – a previously unknown circumstance with ramifications for how tumour cells respond to treatment. This has been shown by Uppsala researcher Fredrik Swartling together with colleagues in the U.S., Canada and England in a study that was published today in the distinguished journal Cancer Cell.

Every year, 80-90 children in Sweden are afflicted with brain tumours, a serious form of paediatric cancer. Today, three of four children who receive treatment survive.

The discovery improves the prospects for finding more effective treatments for forms of paediatric cancer that are currently very difficult to cure and has great significance for understanding how brain tumours arise. The next step is to carry out the clinical analyses necessary for developing drugs that target specific types of brain tumours.

Trials were carried out using immature , or , from such regions of the brain as the cerebellum, cerebrum and brain stem. The stem cells were then compared with tumour cells from more than 100 patients. Cellular origin showed itself to be at least as important a determinant of tumour malignancy as the genetic mutations underlying the transformation of normal cells to tumour cells. The point in time at which tumours arose was also of great relevance to the effectiveness of treatment.

"We can't focus exclusively on mutated genes when looking at cancer," says Fredrik Swartling, who directed the study jointly with paediatric neurologist William Weiss, who works at the University of California children's hospital and brain tumour research center in San Francisco, California, in the U.S. "The status of the cells of origin giving rise to cancer is at least as important from a treatment standpoint. Our study shows that tumours contain markers for these cells of origin."

Brain tumours most often arise on account of accidental genetic mutations. One gene that mutates readily and is well-represented in paediatric is the MYCN cancer gene. Previous research has proposed that patients with high levels of a specific cancer gene like MYCN should be treated in the same way. The current study shows that this is not the case.

"The tumours are more diverse that we believed," Fredrik Swartling says. "It is very important, even for patients who exhibit the exact same mutation of a cancer gene, whether their tumours arose in the cerebellum, cerebrum or brain stem and whether these tumours arose during fetal stages or following birth."

The researchers showed in the study that normal stem cells are transformed into tumour cells in vitro following introduction of the MYCN cancer gene to the cells. Stem cells from an early fetal stage and from a later life juncture were both transformed into tumour cells. The effectiveness of treatment differed, despite the fact that the same had caused the tumours in each case.

That tumours reflect their origins makes it relatively simple to determine the origin of the cancer represented in a tumour biopsy from a patient. The challenge ahead will be to identify reliable markers for tumour origin to enable better judgement about treatment options and ensure the effectiveness of treatment in diverse cases.

"The goal is to develop a range of different treatments for patients of different types," Fredrik Swartling says. "It may take some time before such treatments are available at hospitals, but clinical trials involving drugs similar to those used in the study are already under way, and we are keeping our fingers crossed that the drugs will work as anticipated."

Explore further: RANK protein promotes the initiation, progression and metastasis of human breast cancer

More information: www.cell.com/cancer-cell

Related Stories

RANK protein promotes the initiation, progression and metastasis of human breast cancer

April 24, 2012
Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) have shown that overactivation of the RANK signalling pathway promotes the initiation, progression and metastasis of tumours in human breast epithelial ...

Treatment of common virus can reduce tumour growth

September 27, 2011
Researchers at Karolinska Institutet in Sweden have demonstrated for the first time that it is possible to inhibit the growth of brain tumours by treating the common Cytomegalovirus (CMV). The virus, which is found in a wide ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.